Department of Health and Human Services, National Institutes of Health
Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
Who can apply
- County governments
- Private colleges and universities
- Public and tribal housing authorities
- State governments
- Nonprofits with 501(c)(3) status
- Public and state-controlled colleges
- Tribal organizations
- Independent school districts
- Others (see eligibility details)
- For-profit organizations (not small businesses)
- City or township governments
- Special district governments
- Federally recognized tribal governments
- Nonprofits without 501(c)(3) status
- Small businesses
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
About this grant
The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.
Topics
GrantCalendar is not affiliated with Department of Health and Human Services. Details can change, so confirm everything on the official listing before you apply. Spotted a mistake? Tell us.
Similar open grants
- Closes in 12 days
- Closes in 13 days
- Closes in 20 days
- Closes in 23 days
- Closes in 24 days
Get new grants every Monday
One short email with new grants and deadlines coming up in the next two weeks. Unsubscribe in one click.